EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Pharmacogenetics of incretin-based therapies

Alena Stančáková Yaluri, Anna Ürgeová, Michal Maršálek, Martin Javorský, Ivan Tkáč

Postgraduate Medical Journal · 2026

DOI: 10.1093/postmj/qgaf232 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Postgraduate Medical Journal, 2026. Verfasst von Alena Stančáková Yaluri und 4 weiteren Autor:innen. Beteiligte Einrichtung: 4th Department of Internal Medicine, P.J. Šafárik University in Košice, Medical Faculty, and L. Pasteur University Hospital, Rastislavova 43, 04001 K…. Hauptthemen laut MEDLINE: Incretins, Diabetes Mellitus, Type 2, Pharmacogenetics, Dipeptidyl-Peptidase IV Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 79 Literaturangaben. Gefördert von: The Ministry of Education, Research, Development, and Youth of the Slovak Republic and Slovak Academy of Science VEGA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Interindividual variability in the efficacy of various glucose-lowering drugs has been previously reported and partly explained by genetic variants. The aim of this review was to summarize currently available information on pharmacogenetic studies of the efficacy of incretin-based therapies such as glucagon-like peptide 1 (GLP-1) receptor agonists (GLP1RA) and dipeptidyl peptidase 4 (DPP-4i) inhibitors. Several missense variants of the GLP1R gene have been associated with the effects of GLP1RA or DPP-4 inhibitors on glycaemic compensation or weight. Pharmacogenetic effects have also been reported for several type 2 diabetes–associated loci, such as TCF7L2, THADA, MTNR1B, CDKAL1, KCNQ1, KCNJ11, and PAM in candidate gene approach studies. Genome-wide pharmacogenetic studies have identified new genes with potentially relevant pharmacogenetic effects (CTRB1/2, ARRB1, PRKD1). Although none of these genetic associations are currently used in guiding the treatment choices in clinical practice, they offer valuable insights bringing us a little closer to precision medicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IncretinsDiabetes Mellitus, Type 2PharmacogeneticsDipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsHumansGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide-1 Receptor

Stichwörter der Autor:innen

dipeptidyl peptide 4 inhibitorsglucagon-like peptide 1 receptor agonistspharmacogeneticstype 2 diabetes

Substanzen

IncretinsDipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide-1 Receptor

Autor:innen und Institutionen

  • 4th Department of Internal Medicine, P.J. Šafárik University in Košice, Medical Faculty, and L. Pasteur University Hospital, Rastislavova 43, 04001 Košice, Slovakia.

Förderung

  • The Ministry of Education, Research, Development, and Youth of the Slovak Republic and Slovak Academy of Science VEGA

Zitieren

APA

Yaluri, A. S., Ürgeová, A., Maršálek, M., Javorský, M., & Tkáč, I. (2026). Pharmacogenetics of incretin-based therapies. Postgraduate Medical Journal. https://doi.org/10.1093/postmj/qgaf232

Vancouver

Yaluri AS, Ürgeová A, Maršálek M, Javorský M, Tkáč I. Pharmacogenetics of incretin-based therapies. Postgraduate Medical Journal. 2026. doi:10.1093/postmj/qgaf232

BibTeX
@article{Yaluri2026,
  author = {Yaluri, Alena Stančáková and Ürgeová, Anna and Maršálek, Michal and Javorský, Martin and Tkáč, Ivan},
  title = {Pharmacogenetics of incretin-based therapies},
  journal = {Postgraduate Medical Journal},
  year = {2026},
  doi = {10.1093/postmj/qgaf232}
}
Kostenlos starten →